According to data from Grand View Research, the GLP-1RA market in the Asia-Pacific region reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, representing a compound annual growth rate (CAGR) of 14% [1] , making it one of the fastest-growing regions globally
Los agonistas del receptor GLP-1 estimulan la secrecin de insulina, suprimen el glucagn, retrasan el vaciamiento gstrico y reducen el apetito actuando sobre mltiples mecanismos simultneos
The 0.25mg/0.5mg pen is designed for the first 8 weeks of titration and only dispenses those two doses
You have a personal or family history of autoimmune disease
Gan & Lee Pharmaceuticals will receive a one-time, non-refundable upfront payment of USD 5 million
While some patients experience diarrhea, others develop constipation, and many notice changes in bowel frequency or consistency